FCCC LOGO Faculty Publications
Negendank WG , Padavicshaller KA , Li CW , Murphyboesch J , Stoyanova R , Krigel RL , Schilder RJ , Smith MR , Brown TR
Metabolic Characterization of Human Non-Hodgkins-Lymphomas in- Vivo with the Use of Proton-Decoupled Phosphorus Magnetic- Resonance Spectroscopy
Cancer Research. 1995 Aug 1;55(15) :3286-3294
PMID: ISI:A1995RL49300014   
Back to previous list
Abstract
Development of biological and clinical uses of in vivo P-31 magnetic resonance spectroscopy has been hampered by poor anatomic localization of spectra and poor resolution of overlapping signals within phosphomonoester and phosphodiester regions of the spectrum. We applied H-1-decoupling and nuclear Overhauser enhancement to improve resolution of P-31 magnetic resonance spectra accurately localized to 21 non-Hodgkin's lymphomas (NHL) by using three-dimensional chemical shift imaging. All 21 spectra had large phosphomonoester signals (26% of total phosphorus) that contained high amounts of phosphoethanolamine relative to phosphocholine. There were no signals from glycerophosphoethanolamine or glycerophosphocholine but only a broad signal from membrane phospholipids in the phosphodiester region (20% of phosphorus). Prominent nucleoside triphosphates (47% of phosphorus) and low inorganic phosphate (7% of phosphorus) indicate well-perfused tissue with viable cells. Mean intracellular pH was 7.23, These characteristics were similar in all grades and stages of NHL. By analogy with recently reported studies in cell lines in vitro, we hypothesize that the pattern of phospholipid metabolites observed in NHL in vivo is partly a manifestation of sustained activation of phospholipase C or D. The techniques we implemented permitted us to obtain more information about in vivo metabolism of NHL than has heretofore been available. This information is important for the establishment of appropriate experimental models and provides a basis from which to examine potential clinical uses of P-31 magnetic resonance spectroscopy.
Notes
Times Cited: 28 Article RL493 CANCER RES